Sugi Predict

Sugi Predict / Targets / CHRND

CHRND

Acetylcholine receptor subunit delta · Q07001 · CHRND on Sugi Atlas →

18,948 patent compounds predicted against CHRND, 10,562 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Radafaxine Radafaxine (SCHEMBL48964) 1.00 18/20
SCHEMBL306050 SCHEMBL306050 0.46 7/20
SCHEMBL1459633 SCHEMBL1459633 1.00 6/20
SCHEMBL1459699 SCHEMBL1459699 0.76 6/20
SCHEMBL988166 SCHEMBL988166 0.66 6/20
SCHEMBL985563 SCHEMBL985563 0.65 6/20
SCHEMBL988137 SCHEMBL988137 0.60 6/20
SCHEMBL240780 SCHEMBL240780 0.58 6/20
SCHEMBL455131 SCHEMBL455131 0.55 6/20
SCHEMBL455132 SCHEMBL455132 0.55 6/20
SCHEMBL988507 SCHEMBL988507 0.55 6/20
SCHEMBL275641 SCHEMBL275641 0.51 6/20
SCHEMBL489272 SCHEMBL489272 0.42 6/20
SCHEMBL489274 SCHEMBL489274 0.42 6/20
Bupropion Bupropion (SCHEMBL38777) 1.00 5/20
Bupropion Bupropion (SCHEMBL60314) 1.00 5/20
Bupropion Bupropion (SCHEMBL300444) 1.00 5/20
SCHEMBL634327 SCHEMBL634327 1.00 5/20
Bupropion Bupropion (SCHEMBL41602) 0.97 5/20
Bupropion Bupropion (SCHEMBL636116) 0.97 5/20

Clinical trials — most relevant to CHRND by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Efficacy of Ketamine Mouthwash in the Management of Oral and Pharyngeal Toxicity Associated With Head and Neck Chemoradiotherapy: A Phase 2, Simon 2-stage Trial PHASE2WITHDRAWN
Varenicline (Chantix™) for the Treatment of Alcohol Dependence PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia PHASE2COMPLETED
Depressed Mood Improvement Through Nicotine Dosing 3 PHASE2ACTIVE_NOT_RECRUITING
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence PHASE2COMPLETED
Pilot Study of Pyridostigmine Upon Immune Activation in HIV-1 Patients Who Have an Inadequate Immune Response PHASE2COMPLETED
M1 Schizophrenia PET Study PHASE1COMPLETED
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Analgo-Sedative Effects Of Oral, Or Nebulized Ketamine In Pre-schoolers Undergoing Elective Surgery. EARLY_PHASE1COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Immunoadsorption Study Mainz in Adults With Post-COVID Syndrome nanCOMPLETED
Single Photon Emission Computed Tomography to Study Receptors in Parkinson's Disease nanCOMPLETED
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
Nicotinic Receptor Density in Smoking and Nonsmoking Schizophrenics nanWITHDRAWN
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRND binder may also engage these)

ProteinNameSimilarity
P04759 — 1.000 P04759 →
P25110 — 0.998 P25110 →
P02716 — 0.996 P02716 →
P02717 — 0.995 P02717 →
P49580 — 0.992 P49580 →
P05376 — 0.988 P05376 →
P18916 — 0.986 P18916 →
P09484 — 0.986 P09484 →
P02713 — 0.985 P02713 →
P02714 — 0.985 P02714 →
CHRNB2 Neuronal acetylcholine receptor subunit beta-2 0.984 landscape →
P04760 — 0.983 P04760 →
P19370 — 0.982 P19370 →
CHRNA9 Neuronal acetylcholine receptor subunit alpha-9 0.982 landscape →
P09628 — 0.981 P09628 →
Q9ERK7 — 0.981 Q9ERK7 →
P49579 — 0.981 P49579 →
Q8SPU6 — 0.979 Q8SPU6 →
P12390 — 0.979 P12390 →
Q68RJ7 — 0.978 Q68RJ7 →
P04758 — 0.978 P04758 →
P25109 — 0.978 P25109 →
P54131 — 0.978 P54131 →
P12392 — 0.977 P12392 →
P26153 — 0.976 P26153 →
P43144 — 0.976 P43144 →
CHRNG Acetylcholine receptor subunit gamma 0.976 landscape →
CHRNB1 Acetylcholine receptor subunit beta 0.975 landscape →
CHRNA7 Neuronal acetylcholine receptor subunit alpha-7 0.975 landscape →
Q05941 — 0.975 Q05941 →